Nov.26 -- AstraZeneca Plc is likely to conduct an additional global trial to assess the efficacy of its Covid-19 vaccine, according to Pascal Soriot, the company’s chief executive officer, after current studies raised questions over its level of protection. Suzi Ring reports on "Bloomberg Markets: European Close."